A dysfunctional glutamatergic system is thought to be central to the negative symptoms and cognitive deficits recognized as determinant to the poor quality of life of people with schizophrenia. Modulating glutamate uptake has, thus, been suggested as a novel target for antipsychotics. Alstonine is an indole alkaloid sharing with atypical antipsychotics the profile in animal models relevant to schizophrenia, though divergent in its mechanism of action. The aim of this study was to evaluate the effects of alstonine on glutamate uptake. Additionally, the effects on glutathione content and extracellular S100B levels were assessed. Acute hippocampal slices were incubated with haloperidol (10 lM), clozapine (10 and 100 lM) or alstonine (1-100 lM), alone or in combination with apomorphine (100 lM), and 5-HT 2 receptor antagonists (0.01 lM altanserin and 0.1 lM SB 242084). A reduction in glutamate uptake was observed with alstonine and clozapine, but not haloperidol. Apomorphine abolished the effect of clozapine, whereas 5-HT 2A and 5-HT 2C antagonists abolished the effects of alstonine. Increased levels of glutathione were observed only with alstonine, also the only compound that failed to decrease the release of S100B. This study shows that alstonine decreases glutamate uptake, which may be beneficial to the glutamatergic deficit observed in schizophrenia. Noteworthily, the decrease in glutamate uptake is compatible with the reversal of MK-801-induced social interaction and working memory deficits. An additional potential benefit of alstonine as an antipsychotic is its ability to increase glutathione, a key cellular antioxidant reported to be decreased in the brain of patients with schizophrenia. Adding to the characterization of the novel mechanism of action of alstonine, the lack of effect of apomorphine in alstonine-induced changes in glutamate uptake reinforces that D 2 receptors are not primarily implicated. Though clearly mediated by 5-HT 2A and 5-HT 2C serotonin receptors, the precise mechanisms that result in the effects of alstonine on glutamate uptake warrant elucidation.
Introduction
With lifetime prevalence commonly estimated in 1% of the population, schizophrenia is a severe psychiatric disorder marked by profound retreat from reality and incapacitating cognitive deficits. It belongs to a group of complex multifactorial disorders, for which the etiology is understood as the intricate interaction between genetic and environmental factors (Gogos and Gerber, 2006; van Os et al., 2010) .
The observations of the behavioral effects induced by phencyclidine (PCP), an antagonist of glutamate NMDA receptors, prompted the idea of a glutamatergic dysfunction in the pathophysiology of schizophrenia. PCP, as well as the related drugs ketamine and MK-801, induce in normal volunteers psychosis-like and neurocognitive disturbances similar to those of schizophrenia; unlike dopaminergic agonists, these drugs mimic all the symptoms dimensions of the disease (Javitt, 2010) . It is now widely accepted that the dopaminergic alterations classically associated to schizophrenia may, in fact, be secondary to an underlying deficit in glutamatergic transmission (Carlsson, 2006; Marek et al., 2010) . Of note, Stone et al. (2010) reported in prodromic subjects with mild psychotic symptoms a negative relationship between hippocampal glutamate levels and striatal [
18 F]-DOPA uptake, reinforcing the idea of a coupling between glutamatergic transmission and striatal dopaminergic activity. Glutamate is released into the synapse and rapidly removed by a family of excitatory amino acid transporters (EAATs) localized in neurons and glial cells. Five members of EAATs have been identified and termed EAAT1-5 to human homologs, or GLAST, GLT-1 and EAAC-1 representing the rodent homologs of EAATs1-3, respectively (Kanai and Hediger, 1992; Pines et al., 1992; Storck et al., 1992; Fairman et al., 1995; Arriza et al., 1997) . EAAT2/ GLT-1 is predominantly expressed in astrocytes and provides more than 90% of total glutamate uptake in the central nervous system (Tanaka et al., 1997) .
Given that astrocytes are fundamental in the control of glutamate homeostasis, a significant role has recently been assigned to glial-neuronal interactions in the pathophysiology of schizophrenia. There is increasing evidence that structural and functional alterations in glial cells are present in the brain of people with schizophrenia (Cotter et al., 2001; Kondziella et al., 2006; Bernstein et al., 2009; Katsel et al., 2011) . Additionally, a DNA array study showed that the genes most frequently altered in the disorder are related to glial function (Sugai et al., 2004) . Signaling molecules, such as S100B and GFAP, have also been examined as markers of astrocytic function. Several studies reported increased S100B levels in the serum or cerebrospinal fluid (CSF) of patients with schizophrenia (Wiesmann et al., 1999; Lara et al., 2001; Rothermundt et al., 2001 Rothermundt et al., , 2004a Rothermundt et al., ,b, 2007 Schroeter et al., 2003; Schmitt et al., 2005) ; however, the effects of antipsychotic drugs in this parameter remain unclear (Steiner et al., 2010) .
It is undisputable that over the past decades major advances have been accomplished in the understanding of the neurobiological processes involved in schizophrenia. The acquired knowledge, however, has not translated into better treatment options, since all currently available antipsychotics share their mechanism of action with drugs discovered almost 60 years ago. Moreover, the modest and controversial benefits of antipsychotics on cognitive deficits and negative symptoms, combined with the unwanted side effects, result in high rates of treatment discontinuation (Lieberman et al., 2005) . The development of drugs with innovative mechanisms of action is, thus, required (Gründer et al., 2009) .
We have previously reported the properties of alstonine, a putative antipsychotic which has consistently shown anxiolytic and antipsychotic-like effects in several mouse models (Costa-Campos et al., 1998 de Moura Linck et al., 2008) . Alstonine is an indole alkaloid present in plant species traditionally used in Nigeria to treat mentally ill patients (Costa-Campos et al., 1998) . Although its mechanism of action remains unclear, D 2 receptors do not seem to be directly involved in its antipsychotic-like effects, and blockade of 5-HT 2A/C receptors by ritanserin abolished its anxiolytic action (Costa-Campos et al., 2004a) . Recent data showed that the ability of alstonine to counteract MK-801-induced working memory deficit, social withdrawal and hyperlocomotion was also blocked by pretreatment with ritanserin (Linck et al., 2012) .
Considering the growing role attributed to astrocytes in brain signaling and the recognized association between glutamatergic dysfunction and schizophrenia, the aim of this study was to evaluate the effects of alstonine on glutamate uptake and other astrocytic parameters. The effects of alstonine were compared to typical and atypical antipsychotics (haloperidol and clozapine, respectively). For this purpose, we used acute hippocampal slices, elected for preserving the neuronal circuitry and the interactions between neurons and glia.
Materials and methods

Animals
Experiments were performed with 30-day-old male Wistar rats obtained from our breeding colony (Department of Biochemistry, UFRGS, Porto Alegre, Brazil). Animals were maintained under controlled environmental conditions (12-h light/dark cycle at a constant temperature of 22 ± 1°C) with free access to food and water. The study was approved by the University Ethics Committee (approval #18237), and followed institutional policies on experimental animal handling. All efforts were made to minimize animal suffering, to reduce the number of animals used, and to utilize alternatives to in vivo techniques.
Drugs and reagents
Alstonine hydrochloride was isolated from Picralima nitida Th. & H. Dur. (Apocynaceae) by Christopher O. Okunji, as earlier described (Okunji et al., 2005) . Clozapine, altanserin and SB 242084 were purchased from Sigma Chemical Co. (St. Louis, MO, USA), apomorphine was purchased from Research Biochemicals International (Natick, MA, USA), DL-threo-b-benzyloxyaspartic acid (DL-TBOA) was acquired from Tocris Bioscience (Bristol, UK) and haloperidol was used as commercial Haldol Ò from Janssen-Cilag Farmacêutica Ltd. (São Paulo, SP, Brazil). Monoclonal anti-S100B antibody (SHB1), 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (Hepes), o-phenylenediamine (OPD), 3-(4,5-dimethylthiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) and L-glutamate were purchased from Sigma (St. Louis, MO, USA), polyclonal rabbit anti-S100 from Dako (Glostrup, Denmark), and horseradish peroxidase-conjugated anti-rabbit IgG and L-[2,3-3 H]-glutamate from
Amersham International (Buckinghamshire, UK). All other chemicals were purchased from local commercial suppliers.
Hippocampal slices
Rats were killed by decapitation. Hippocampi were removed and sliced in transverse sections of 0.3 mm using a McIlwain tissue chopper. Slices were transferred to 24-well plates containing 0.3 mL of Hepes-buffered saline solution (120 mM NaCl, 2 mM KCl, 1 mM CaCl 2 , 1 mM MgSO 4 , 1 mM KH 2 PO 4 , 10 mM glucose and 25 mM Hepes, pH 7.4) per well. The medium was changed every 15 min for 2 h at room temperature. After this stabilization period, the drugs were added and the slices incubated for 1 h at 30°C. Treatments consisted of haloperidol (10 lM), clozapine (10 and 100 lM), alstonine (1, 10 and 100 lM), apomorphine (100 lM), altanserin (0.01 lM) and SB 242084 (0.1 lM). Drug concentrations were chosen based on pilot experiments and/or previous reports (Steiner et al., 2010; Nardin et al., 2011) . All experiments were performed in triplicate (three slices from the same animal were used for each treatment condition).
Glutamate uptake
After the incubation period, the medium was replaced by Hank's balanced salt solution (HBSS) containing 137 mM NaCl, 0.63 mM Na 2 HPO 4 , 4.17 mM NaOHCO 3 , 5.36 mM KCl, 0.44 mM KH 2 PO 4 , 1.26 mM CaCl 2 , 0.41 mM MgSO 4 , 0.49 mM MgCl 2 and 5.55 mM glucose, pH 7.4. The slices were maintained at 35°C, and the assay was started by adding 0.1 mM L-glutamate and 0.66 lCi/mL L-[2,3-3 H]-glutamate; this high unlabeled glutamate concentration renders the assay insensitive to changes in glutamate release. Incubation was stopped after 5 min by removing the medium and rinsing the slices three times with ice-cold HBSS; it has been shown that up to 5 min the glutamate uptake is linear in this slice preparation (Thomazi et al., 2004) . Slices were then lysed in a solution containing 0.5 N NaOH. Sodium-independent (nonspecific) uptake was determined using a solution with Nmethyl-D-glutamine instead of NaCl. Sodium-dependent glutamate uptake was obtained by subtracting nonspecific uptake. Radioactivity was measured with a scintillation counter (2800TR TriCarb Liquid Scintillation Analyzer, Perkin-Elmer, Waltham, MA, USA). Final glutamate uptake was expressed as nmol/mg protein/min.
As an indication that most of the sodium-dependent uptake in this slice preparation is glutamate transporter-dependent, 75% of the uptake was inhibited by the transporter blocker DL-TBOA (300 lM), in comparison to 85% inhibition in sodium-free conditions (basal: 6463 ± 699, sodium-free: 940 ± 185, 300 lM DL-TBOA: 1613 ± 161, in cpm, data not shown).
Glutathione content
Total reduced glutathione content was determined as previously described (Browne and Armstrong, 1998) . Briefly, slices were homogenized in sodium phosphate buffer (0.1 M, pH 8.0) containing 5 mM EDTA and protein was precipitated with 1.7% meta-phosphoric acid. Supernatant was assayed with o-phthaldialdehyde (1 mg/ml of methanol) at room temperature for 15 min. Fluorescence was measured using excitation and emission wavelengths of 350 and 420 nm, respectively. A calibration curve was performed with standard glutathione solutions (0-500 lM). Final concentrations were calculated and expressed as nmol/mg protein.
Extracellular S100B content
Immediately after the incubation period, 10 lL of medium were collected and kept in À20°C until S100B levels were determined by ELISA, as previously described (Leite et al., 2008) . Briefly, 50 lL of Tris buffer were added to the samples and incubated for 2 h in a microtiter plate previously coated with monoclonal anti-S100B. Polyclonal anti-S100 was incubated for 30 min; peroxidaseconjugated anti-rabbit antibody was added for additional 30-min incubation. The color reaction with o-phenylenediamine was measured at 492 nm. The standard S100B curve ranged from 0.002 to 1 ng/mL. Results were expressed as a percentage of the control.
Cell viability and integrity
Cell viability was assayed by the colorimetric MTT reduction method (Hansen et al., 1989) . Briefly, slices were incubated with 0.5 mg/mL of MTT at 30°C for 30 min. The formazan product generated during the incubation was solubilized in dimethyl sulfoxide (DMSO). Absorbance values were measured at 560 and 630 nm. Cell integrity was indicated by lactate dehydrogenase (LDH) activity in the incubation medium. Determination was carried out by a colorimetric commercial kit (Doles Reagentes e Equipamentos para Laboratórios Ltd., Brazil) according to the manufacturer's instructions. Results were expressed as percentage of the control.
Protein content
Total protein concentrations were determined by the modified method of Lowry (Peterson, 1977) , using bovine serum albumin as standard.
Statistical analysis
Data were analyzed by one-way ANOVA followed by NewmanKeuls post hoc test. Two-way ANOVA was employed when analyzing the effects of two independent variables. GraphPad Prism 5 for Windows was used for the statistical analysis; p < 0.05 was set as statistically significant. Results represent mean + SEM.
Results
In order to verify if cell viability (Fig. 1A) and integrity (Fig. 1B) were not compromised by drug treatments, two assays were performed in parallel; no significant differences were observed for MTT reduction (F 6, 53 = 2.15, p > 0.05) or LDH activity (F 6, 56 = 0.25, p > 0.05), indicating that slices remained viable and integrate. These same parameters were also evaluated for apomorphine, altanserin and SB 242084, with no significant alterations (data not shown).
Glutamate uptake in hippocampal slices was significantly (F 6, 55 = 8.63, p < 0.0001) altered by treatments (Fig. 2A) . Post hoc analysis revealed that 10 and 100 lM clozapine and alstonine significantly decreased glutamate uptake (49% and 59%, respectively, at highest concentrations). The co-incubation of the drugs with 100 lM apomorphine also affected glutamate uptake (F 7, 50 = 9.83, p < 0.0001), as shown in Fig. 2B . Post hoc analysis indicated that apomorphine had no effects per se, and did not interfere with alstonine-induced decrease in glutamate uptake; interestingly, however, the decrease in glutamate uptake induced by clozapine at 100 lM was abolished in the presence of apomorphine.
The role of 5-HT 2A and 5-HT 2C receptors on alstonine-induced reduction of glutamate uptake was investigated. Two-way ANOVA revealed a main effect of 100 lM alstonine (F 1, 26 = 11.79, p < 0.01), and of the 5-HT 2A antagonist altanserin (F 1, 26 = 4.23, p < 0.05), as well as interaction between alstonine and altanserin (F 1, 26 = 14.25, p < 0.001) (Fig. 3A) . Two-way ANOVA also revealed a main effect of 100 lM alstonine (F 1, 26 = 71.89, p < 0.01) and of the 5-HT 2C antagonist SB 242084 (F 1, 26 = 7.46, p < 0.05), as well as interaction between alstonine and SB 242084 (F 1, 26 = 40.46, p < 0.001) (Fig. 3B) . These results show that the effect of alstonine on glutamate uptake involve both 5-HT 2A and 5-HT 2C receptors. Total glutathione content was significantly altered in hippocampal slices submitted to drug treatments (F 6, 50 = 3.76, p < 0.01), as shown in Fig. 4 . Post hoc analysis indicated that only alstonine in its highest concentration (100 lM) was able to increase (70%) glutathione levels in comparison to control.
As shown in Fig. 5 , treatment with antipsychotic drugs significantly altered S100B secretion (F 6, 133 = 3.15, p < 0.01). Post hoc analysis revealed that haloperidol at 10 lM and clozapine at 100, but not 10 lM, reduced (29% and 25%, respectively) the secretion of this protein.
Discussion
In the present study, we show the effects of the alkaloid alstonine and known antipsychotics in biochemical parameters relevant to the pathophysiological basis of schizophrenia. One significant finding is the observation that alstonine and clozapine, but not haloperidol, reduced glutamate uptake in acute hippocampal slices. Though the mechanism by which glutamate uptake is reduced requires further clarification, a generalized effect on sodium gradients seems unlikely given the absence of evidence that antipsychotics induce changes in Na + , K + -ATPase activity or membranes sodium gradients (Seibt et al., 2012; López Ordieres et al., 2005) , as well as the reversal seen with the serotonin antagonists. Specifically for alstonine, no changes in dopamine or serotonin levels were seen in the striatum from mice acutely treated with alstonine in behaviorally effective doses (Linck et al., 2011) , again arguing against a generalized effect that would also alter the sodium-dependent monoamine transporters. The nearly complete 5 . Effects of haloperidol, clozapine and alstonine on S100B secretion. Hippocampal slices were incubated for 1 h with the drugs and S100B levels in the medium were measured. Data represent mean + SEM and are expressed as percentage of control. Ã=p < 0.05 compared to control. One-way ANOVA/Newman-Keuls.
inhibition of glutamate uptake in the presence of the transport inhibitor TBOA advances the idea that it is the high-affinity sodium-dependent glutamate transport that was evaluated in this study.
It is known that it is the glutamate transport by astrocyte that determines the availability of released glutamate to pre-and post-synaptic receptors, as well as its spillover to extra-synaptic sites (Diamond, 2001; Dunlop et al., 2006) . Several studies have documented altered expression and function of astrocytic glutamate transporters in schizophrenia (Ohnuma et al., 1998 (Ohnuma et al., , 2000 Smith et al., 2001; Matute et al., 2005) , and it has been suggested that an increased glutamate uptake by astrocytes may considerably contribute to its purported glutamatergic hypofunction (Nanitsos et al., 2005) . Reducing glutamate uptake can, thus, be regarded as a viable strategy to improve glutamatergic function, and is compatible with the ability of alstonine and clozapine to counteract MK-801-induced behavioral effects. In agreement with our findings, it has been previously reported that clozapine reduced both the expression of the GLT-1 glutamate transporter and the glutamate uptake in astrocyte cultures , as well as the glutamate transport in rat prefrontal cortex (Melone et al., 2003) . Moreover, the atypical antipsychotic aripiprazole decreased the gene expression of glial and neuronal glutamate transporters in cortical and hippocampal regions, suggesting a transcriptional mechanism to strengthen glutamatergic transmission (Segnitz et al., 2009 ). On the contrary, selective D 2 receptor antagonists, such as haloperidol, were shown to be less effective than atypical antipsychotics to attenuate the effects induced by NMDA receptor antagonists , in agreement with the lack of effects of haloperidol on glutamate uptake. It remains to be clarified which subtypes of transporters are altered by alstonine, as well as if the mechanism is common to the atypical agents above mentioned.
Although reducing glutamate uptake can be advantageous to minimize glutamatergic hypofunction and is suggested as a novel target for antipsychotics (Nanitsos et al., 2005) , it is well established that excessive glutamate availability may overactivate NMDA and AMPA receptors leading to excitotoxicity. In the case of alstonine, the glutamatergic modulation through reduced uptake does not seem to reach excitotoxic levels, since unlike clozapine alstonine lacks proconvulsant properties in a kindling paradigm (Costa-Campos et al., 2004b) . Congruent with the evidence that alstonine lacks affinity for dopamine receptors (Costa-Campos et al., 1998) , the co-incubation with the dopamine agonist apomorphine did not alter the alstonine-induced decrease in glutamate uptake, but abolished that of clozapine.
Save for dopamine and glutamate, it has been shown that some atypical antipsychotics act as 5-HT 2A/C receptor antagonists and/or inverse agonists . This serotonergic modulation is thought to be decisive for the alleged advantages of these medications over classical agents (Gründer et al., 2009 ). However, agonists of these receptors may also present a desirable antipsychotic-profile, since activation of 5-HT 2A receptors enhances dopamine release, whereas 5-HT 2C activation inhibits it (Bortolozzi et al., 2005; Di Giovanni et al., 2006; Pehek et al., 2006; Huang et al., 2011) . Several groups have demonstrated that astrocytes express various 5-HT receptor subtypes, including 5-HT 2A and 5-HT 2C (Deecher et al., 1993; Merzak et al., 1996; Hirst et al., 1998; Cohen et al., 1999) . One known effect of serotonin and selective serotonin reuptake inhibitors at these receptors is the elevation of intracellular calcium levels in glial cells (Hagberg et al., 1998; Schipke et al., 2011) , which was shown to trigger the efflux of glutamate (Meller et al., 2002) . It is conceivable that changes in astrocytic glutamate uptake may also result from changes in calcium levels when these serotonin receptors are modulated. We here show that alstonineinduced decrease in glutamate uptake is prevented by both altanserin and SB 242084, consistent with the ability of ritanserin to prevent the behavioral effects of alstonine (Costa-Campos et al., 2004a; Linck et al., 2012) . The proposal that serotonin is associated with alstonine mechanism of action is also supported by the increased levels of serotonin and 5-HIAA in frontal cortex and striatum from alstonine treated mice (Linck et al., 2011) . Though it is clear that alstonine modulates serotonin pathways, it remains to be clarified whether alstonine activates receptors, increases serotonin release, or both. Likewise, since 5-HT 2A/C receptors are expressed in both neurons and astrocytes, data from cultured astrocytes controlled for the expression of EAAT1/EAAT2 would better clarify if glutamate transport is affected in neurons, astrocytes or both. Most importantly, the congruence from in vitro and in vivo data shows that whatever the specific transport affected, glutamatergic transmission is significantly modulated by alstonine.
Glutathione is a tripeptide consisting of glycine, cysteine and glutamate, which participates in essential aspects of cellular homeostasis. The cellular ability to synthesize glutathione is an important factor in the management of oxidative stress-induced neurotoxicity. Schizophrenia has been consistently associated with reduced levels of glutathione, leading to potential NMDA receptors dysfunction (Do et al., 2000; Steullet et al., 2006; Yao et al., 2006; Gysin et al., 2007; Matsuzawa et al., 2008; Raffa et al., 2009; Gawryluk et al., 2011; Micó et al., 2011) . Our results show that, among the antipsychotics studied, only alstonine was able to increase the intracellular levels of glutathione in hippocampal slices; this may represent an additional valuable feature of alstonine. The alstonine-induced increment in glutathione content could result from increased synthesis, regeneration (NADPH-dependent), sparing or decreased exportation by astrocytes (for a review see Hirrlinger and Dringen, 2010) . Additional experiments, including those with astrocyte cultures, are required to elucidate the precise mechanism(s) by which alstonine increases glutathione. S100B is a calcium-binding protein secreted by astrocytes into the synapse, where it is thought to participate in synaptic plasticity (Nishiyama et al., 2002) , being neurotrophic at nanomolar and apoptotic at micromolar levels (Ahlemeyer et al., 2000; Kögel et al., 2004) . Increased serum and CSF S100B levels in patients with schizophrenia have been interpreted as a marker of structural damage or, alternatively, as a sign of increased astrocyte activation (Wiesmann et al., 1999) . It has been suggested that antipsychotic drugs could normalize these elevated levels (Ling et al., 2007; Steiner et al., 2009 Steiner et al., , 2010 Nardin et al., 2011) . Consistent with results obtained by Steiner et al. (2010) in C6 and OLN-93 cell cultures, we here show that both the typical antipsychotic haloperidol and the atypical clozapine decreased the release of S100B in hippocampal slices. In contrast, alstonine did not alter S100B levels, again reinforcing differences in receptor targets between alstonine and known antipsychotics. Considering that the mechanism of S100B secretion remains unclear, it is of interest to evaluate the effects of alstonine in S100B levels under pharmacological conditions of dopaminergic activation before the meaning of this result can be properly addressed.
Conclusions
The key finding of this study is the decrease in glutamate uptake induced by alstonine, and its mediation by 5-HT 2A and 5-HT 2C receptors. A growing body of evidence suggests that particularly the cognitive and negative symptoms of schizophrenia result from a dysfunctional glutamatergic system. Consequently, decreasing glutamate uptake may represent an important feature for developing newer antipsychotic medication, especially effective in the symptoms that are currently undertreated.
